SPY363.67+1.01 0.28%
DIA299.24+0.50 0.17%
IXIC12,205.85+111.44 0.92%

Co-Diagnostics, Inc. Receives CE Markings For Logix Smart ABC And SARS-CoV-2 2-Gene Multiplex Tests

SALT LAKE CITY, Nov. 17, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today

· 11/17/2020 06:31

SALT LAKE CITY, Nov. 17, 2020 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ ABC (Influenza A/B, SARS-CoV-2) and its Logix Smart™ SARS-CoV-2 (genes RdRp/E) multiplex test for multiple targets of the SARS-CoV-2 genome have both obtained regulatory authorization to be sold as in vitro diagnostics ("IVD") for the diagnosis of COVID-19 in markets that accept CE-markings, and are now available for purchase from the Company's Utah-based ISO-13485:2016 certified facility.